Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors (vol 12, 2016, 2021)

被引：4
|
作者：
Iketani, Sho
Forouhar, Farhad
Liu, Hengrui
Hong, Seo Jung
Lin, Fang-Yu
Nair, Manoj S.
Zask, Arie
Huang, Yaoxing
Xing, Li
Stockwell, Brent R.
Chavez, Alejandro
Ho, David D.
机构：
[1] Aaron Diamond AIDS Research Center, Columbia University Irving Medical Center, New York, NY
[2] Department of Microbiology and Immunology, Columbia University Irving Medical Center, New York, NY
[3] Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY
[4] Department of Chemistry, Columbia University, New York, NY
[5] Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY
[6] WuXi AppTec, Cambridge, MA
[7] Department of Biological Sciences, Columbia University, New York, NY
来源：
NATURE COMMUNICATIONS | 2021年 / 12卷 / 01期
基金：
美国国家卫生研究院;
关键词：
D O I：
10.1038/s41467-021-23082-3
中图分类号：
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号：
07 ; 0710 ; 09 ;
摘要：
We report the identification of three structurally diverse compounds – compound 4, GC376, and MAC-5576 – as inhibitors of the SARS-CoV-2 3CL protease. Structures of each of these compounds in complex with the protease revealed strategies for further development, as well as general principles for designing SARS-CoV-2 3CL protease inhibitors. These compounds may therefore serve as leads for the basis of building effective SARS-CoV-2 3CL protease inhibitors. © 2021, The Author(s).
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Effect of Renal Impairment on Pharmacokinetics and Safety of Ensitrelvir, a SARS-CoV-2 3CL Protease Inhibitor
    Katsube, Takayuki
    Kezbor, Safwan
    Shimizu, Ryosuke
    Kubota, Ryuji
    INFECTIOUS DISEASES AND THERAPY, 2024, 13 (03) : 597 - 607
  • [42] Global prevalence of SARS-CoV-2 3CL protease mutations associated with nirmatrelvir or ensitrelvir resistance
    Ip, Jonathan Daniel
    Chu, Allen Wing-Ho
    Chan, Wan-Mui
    Leung, Rhoda Cheuk-Ying
    Abdullah, Syed Muhammad Umer
    Sun, Yanni
    To, Kelvin Kai -Wang
    EBIOMEDICINE, 2023, 91
  • [43] Design, synthesis, and evaluation of trifluoromethyl ketones as inhibitors of SARS-CoV 3CL protease
    Shao, Yi-Ming
    Yang, Wen-Bin
    Kuo, Tun-Hsun
    Tsai, Keng-Chang
    Lin, Chun-Hung
    Yang, An-Suei
    Liang, Po-Huang
    Wong, Chi-Huey
    BIOORGANIC & MEDICINAL CHEMISTRY, 2008, 16 (08) : 4652 - 4660
  • [44] Synthesis, docking studies, and evaluation of pyrimidines as inhibitors of SARS-CoV 3CL protease
    Ramajayam, R.
    Tan, Kian-Pin
    Liu, Hun-Ge
    Liang, Po-Huang
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (12) : 3569 - 3572
  • [45] Chloropyridinyl Esters of Nonsteroidal Anti-Inflammatory Agents and Related Derivatives as Potent SARS-CoV-2 3CL Protease Inhibitors
    Ghosh, Arun K.
    Shahabi, Dana
    Yadav, Monika
    Kovela, Satish
    Anson, Brandon J.
    Lendy, Emma K.
    Bonham, Connie
    Sirohi, Devika
    Brito-Sierra, Carlos A.
    Hattori, Shin-Ichiro
    Kuhn, Richard
    Mitsuya, Hiroaki
    Mesecar, Andrew D.
    MOLECULES, 2021, 26 (19):
  • [46] Screening of drugs by FRET analysis identifies inhibitors of SARS-CoV 3CL protease
    Liu, YC
    Huang, V
    Chao, TC
    Hsiao, CD
    Lin, A
    Chang, MF
    Chow, LP
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2005, 333 (01) : 194 - 199
  • [47] Multidimensional virtual screening approaches combined with drug repurposing to identify potential covalent inhibitors of SARS-CoV-2 3CL protease
    Wang, Ying
    Gao, Qiushuang
    Yao, Peng
    Yao, Qizheng
    Zhang, Ji
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2023, 41 (24): : 15262 - 15285
  • [48] Pharmacokinetic and Pharmacodynamic Analysis of the 3CL Protease Inhibitor Ensitrelvir in a SARS-CoV-2 Infection Mouse Model
    Fukao, Keita
    Nobori, Haruaki
    Kuroda, Takayuki
    Baba, Kaoru
    Matsumoto, Kazumi
    Tanaka, Yukari
    Tachibana, Yuki
    Kato, Teruhisa
    Shishido, Takao
    VIRUSES-BASEL, 2023, 15 (10):
  • [49] DNA encoded peptide library for SARS-CoV-2 3CL protease covalent inhibitor discovery and profiling
    Xing, Yuyu
    Zhang, Huiya
    Wang, Yanhui
    Zong, Zhaoyun
    Bogyo, Matthew
    Chen, Shiyu
    RSC CHEMICAL BIOLOGY, 2024, 5 (07): : 691 - 702
  • [50] Discovery of a novel benzimidazole conjugated quinazolinone derivative as a promising SARS-CoV-2 3CL protease inhibitor
    Hue, Bui Thi Buu
    Giang, Huynh Nguyet Huong
    Nguyen, Cuong Quoc
    Chou, Feng-Pai
    Thanh, Danh La Duc
    Tran, Quang De
    Hieu, Vo Trung
    Mai, Lam Hoang Phuong
    Lin, Hong-Cheu
    Wu, Tung-Kung
    RSC ADVANCES, 2024, 14 (46) : 33820 - 33829
12345